1. Home
  2. GROV vs SCYX Comparison

GROV vs SCYX Comparison

Compare GROV & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

SELL

Current Price

$1.01

Market Cap

44.8M

ML Signal

SELL

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.03

Market Cap

44.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROV
SCYX
Founded
2016
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
44.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
GROV
SCYX
Price
$1.01
$4.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $36.33
AVG Volume (30 Days)
78.4K
★ 282.6K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
55.26
★ 61.36
EPS
★ N/A
N/A
Revenue
★ $173,716,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.14
$977.86
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.86
$0.66
52 Week High
$1.57
$6.09

Technical Indicators

Market Signals
Indicator
GROV
SCYX
Relative Strength Index (RSI) 46.30 37.46
Support Level $0.99 $3.52
Resistance Level $1.12 $4.30
Average True Range (ATR) 0.05 0.42
MACD -0.00 -0.07
Stochastic Oscillator 22.73 3.34

Price Performance

Historical Comparison
GROV
SCYX

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: